TNSN00226A1 - Composes morpholiniques antagonistes du recepteur de la nk-1 - Google Patents

Composes morpholiniques antagonistes du recepteur de la nk-1

Info

Publication number
TNSN00226A1
TNSN00226A1 TNTNSN00226A TNSN00226A TNSN00226A1 TN SN00226 A1 TNSN00226 A1 TN SN00226A1 TN TNSN00226 A TNTNSN00226 A TN TNSN00226A TN SN00226 A TNSN00226 A TN SN00226A TN SN00226 A1 TNSN00226 A1 TN SN00226A1
Authority
TN
Tunisia
Prior art keywords
morpholinic
compounds
receptor antagonist
receptor
compound
Prior art date
Application number
TNTNSN00226A
Other languages
English (en)
Inventor
Maria Ballard Theresa
Sleight Andrew
Andrew Higgins Guy
Hoffmann Torsten
Maria Poli Sonia
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of TNSN00226A1 publication Critical patent/TNSN00226A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

L'INVENTION A TRAIT A UN COMPOSE DE FORMULE : QUI EST LE 2- (3,5-BIS -TRIFLUOROMETHYLPHENYL)- N-METHYL- N (6-MORPHOLIN-4-YL-4-O-TOLYLPYRIDIN-3-YL)- ISOBUTYRAMIDE. ON A TROUVE QUE LE COMPOSE A UNE AFFINITE POUR LE RECEPTEUR DE LA NK-1 ET EN OUTRE, IL EST UTILE DANS LE TRAITEMENT DE MALADIES AYANT UN RAPPORT AVEC CE RECEPTEUR.
TNTNSN00226A 1999-11-29 2000-11-29 Composes morpholiniques antagonistes du recepteur de la nk-1 TNSN00226A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99123685 1999-11-29

Publications (1)

Publication Number Publication Date
TNSN00226A1 true TNSN00226A1 (fr) 2002-05-30

Family

ID=8239481

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN00226A TNSN00226A1 (fr) 1999-11-29 2000-11-29 Composes morpholiniques antagonistes du recepteur de la nk-1

Country Status (50)

Country Link
EP (1) EP1103545B1 (fr)
JP (1) JP3480835B2 (fr)
KR (1) KR100390117B1 (fr)
CN (1) CN1152016C (fr)
AR (1) AR033659A1 (fr)
AT (1) ATE253561T1 (fr)
AU (1) AU775292B2 (fr)
BG (1) BG64622B1 (fr)
BR (1) BRPI0005616B8 (fr)
CA (1) CA2326529C (fr)
CO (1) CO5251405A1 (fr)
CZ (1) CZ299286B6 (fr)
DE (2) DE60006340T2 (fr)
DK (1) DK1103545T3 (fr)
DO (1) DOP2000000106A (fr)
EA (1) EA004404B1 (fr)
ES (2) ES2208205T3 (fr)
FR (1) FR2801590A1 (fr)
GB (1) GB2356863A (fr)
GC (1) GC0000151A (fr)
GE (1) GEP20022763B (fr)
GT (1) GT200000197A (fr)
HK (1) HK1036759A1 (fr)
HR (1) HRP20000809A2 (fr)
HU (1) HU224703B1 (fr)
ID (1) ID28483A (fr)
IL (1) IL139868A (fr)
IS (1) IS2212B (fr)
IT (1) IT1320120B1 (fr)
JO (1) JO2298B1 (fr)
MA (1) MA26754A1 (fr)
MX (1) MXPA00011672A (fr)
MY (1) MY127426A (fr)
NO (1) NO317264B1 (fr)
NZ (1) NZ508386A (fr)
OA (1) OA11513A (fr)
PA (1) PA8507201A1 (fr)
PE (1) PE20010901A1 (fr)
PL (1) PL195957B1 (fr)
PT (1) PT1103545E (fr)
SG (1) SG97171A1 (fr)
SI (1) SI1103545T1 (fr)
SK (1) SK285373B6 (fr)
SV (1) SV2002000227A (fr)
TN (1) TNSN00226A1 (fr)
TR (1) TR200302077T4 (fr)
UA (1) UA70326C2 (fr)
UY (1) UY26458A1 (fr)
YU (1) YU73400A (fr)
ZA (1) ZA200006964B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1394150T3 (da) * 1999-02-24 2011-03-21 Hoffmann La Roche 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister
WO2000050398A2 (fr) * 1999-02-24 2000-08-31 F. Hoffmann-La Roche Ag Derives de pyridinyl et de phenyle
KR100501608B1 (ko) * 2000-07-14 2005-07-18 에프. 호프만-라 로슈 아게 4-페닐-피리딘 유도체의 ｎｋ1 수용체의 길항성선구약물로서의 ｎ-산화물
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
IL162733A0 (en) * 2002-01-31 2005-11-20 Hoffmann La Roche Genetic polymorphisms in the preprotachykinin gene
EP1643998B1 (fr) 2003-07-03 2007-08-29 F. Hoffmann-La Roche Ag Antagonistes doubles des recepteurs nk1/nk3 pour traiter la schizophrenie
TWI280239B (en) 2003-07-15 2007-05-01 Hoffmann La Roche Process for preparation of pyridine derivatives
DE602005026669D1 (de) 2004-07-06 2011-04-14 Hoffmann La Roche Herstellungsverfahren für carboxamid-pyridin-derivate als zwischenprodukte bei der synthese von nk-1-rezeptor-antagonisten
UA90708C2 (ru) 2005-02-25 2010-05-25 Ф. Хоффманн-Ля Рош Аг Таблетки с улучшенной дисперсностью лекарственного вещества
DK1863767T3 (da) * 2005-03-23 2009-05-04 Hoffmann La Roche Metabolitter til NK-I-antagonister til emesis
DK1928427T3 (da) * 2005-09-23 2010-03-08 Hoffmann La Roche Hidtil ukendt dosisformulering
EP2129381A1 (fr) 2007-01-24 2009-12-09 Glaxo Group Limited Nouvelles compositions pharmaceutiques
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
MY180206A (en) 2013-03-15 2020-11-25 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
JP5806420B1 (ja) 2013-11-08 2015-11-10 キッセイ薬品工業株式会社 カルボキシメチルピペリジン誘導体
DK3102208T3 (da) 2014-02-07 2021-03-08 Global Blood Therapeutics Inc Krystallinsk polymorf af den frie base af 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyd
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
KR101948238B1 (ko) 2016-08-19 2019-02-14 (주)케어젠 미녹시딜과 펩타이드의 결합체

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2149767T5 (es) * 1991-09-20 2005-06-16 Glaxo Group Limited Nuevo uso medico para antagonistas de taquiquininas.
IL106142A (en) * 1992-06-29 1997-03-18 Merck & Co Inc Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them
IL111960A (en) * 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
SK283070B6 (sk) * 1993-12-29 2003-02-04 Merck Sharp & Dohme Limited Substituované morfolínové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
TW385308B (en) * 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
ATE242243T1 (de) * 1995-03-24 2003-06-15 Takeda Chemical Industries Ltd Zyklische verbindungen, ihre herstellung und ihre verwendung als tachykininrezeptorantagonisten
US5972938A (en) * 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
DK1394150T3 (da) * 1999-02-24 2011-03-21 Hoffmann La Roche 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
KR100501608B1 (ko) * 2000-07-14 2005-07-18 에프. 호프만-라 로슈 아게 4-페닐-피리딘 유도체의 ｎｋ1 수용체의 길항성선구약물로서의 ｎ-산화물
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives

Also Published As

Publication number Publication date
UY26458A1 (es) 2001-05-31
CZ20004399A3 (cs) 2001-07-11
NO20006012D0 (no) 2000-11-28
ID28483A (id) 2001-05-31
EP1103545B1 (fr) 2003-11-05
PA8507201A1 (es) 2002-02-21
DE10058310A1 (de) 2001-05-31
BG104992A (en) 2001-11-30
AR033659A1 (es) 2004-01-07
BR0005616A (pt) 2001-07-17
NO20006012L (no) 2001-05-30
GEP20022763B (en) 2002-08-26
AU7178700A (en) 2001-05-31
CN1297888A (zh) 2001-06-06
ATE253561T1 (de) 2003-11-15
DK1103545T3 (da) 2004-03-15
CA2326529A1 (fr) 2001-05-29
NZ508386A (en) 2003-02-28
TR200302077T4 (tr) 2004-01-21
ZA200006964B (en) 2001-06-05
YU73400A (sh) 2003-02-28
PL195957B1 (pl) 2007-11-30
EA004404B1 (ru) 2004-04-29
HU224703B1 (en) 2006-01-30
KR20010051983A (ko) 2001-06-25
JO2298B1 (en) 2005-09-12
SK285373B6 (sk) 2006-12-07
PT1103545E (pt) 2004-03-31
HUP0004725A2 (hu) 2002-04-29
SK17932000A3 (sk) 2001-11-06
DE60006340T2 (de) 2004-09-09
GC0000151A (en) 2005-06-29
SG97171A1 (en) 2003-07-18
GB0028566D0 (en) 2001-01-10
IS2212B (is) 2007-02-15
EA200001114A3 (ru) 2001-12-24
PL344147A1 (en) 2001-06-04
BRPI0005616B8 (pt) 2021-07-06
BRPI0005616B1 (pt) 2017-12-12
BG64622B1 (bg) 2005-09-30
IS5725A (is) 2001-05-29
CA2326529C (fr) 2009-12-22
JP3480835B2 (ja) 2003-12-22
IT1320120B1 (it) 2003-11-18
HK1036759A1 (en) 2002-01-18
GT200000197A (es) 2002-05-22
CO5251405A1 (es) 2003-02-28
MA26754A1 (fr) 2004-12-20
DE60006340D1 (de) 2003-12-11
NO317264B1 (no) 2004-09-27
AU775292B2 (en) 2004-07-29
ITMI20002575A1 (it) 2002-05-29
KR100390117B1 (ko) 2003-07-04
UA70326C2 (en) 2004-10-15
CZ299286B6 (cs) 2008-06-04
DOP2000000106A (es) 2002-07-30
SV2002000227A (es) 2002-02-05
HU0004725D0 (fr) 2001-02-28
JP2001151754A (ja) 2001-06-05
IL139868A (en) 2009-09-01
MY127426A (en) 2006-11-30
PE20010901A1 (es) 2001-09-20
HRP20000809A2 (en) 2001-12-31
ES2208205T3 (es) 2004-06-16
MXPA00011672A (es) 2002-08-20
ES2171134A1 (es) 2002-08-16
CN1152016C (zh) 2004-06-02
IL139868A0 (en) 2002-02-10
GB2356863A (en) 2001-06-06
EA200001114A2 (ru) 2001-08-27
EP1103545A1 (fr) 2001-05-30
OA11513A (fr) 2004-02-03
SI1103545T1 (en) 2004-02-29
FR2801590A1 (fr) 2001-06-01

Similar Documents

Publication Publication Date Title
TNSN00226A1 (fr) Composes morpholiniques antagonistes du recepteur de la nk-1
MA27557A1 (fr) Derives d'indolyle pyrazinone utiles pour le traitement des maladies et des troubles hyperproliferants associes a l'angiogenese
DK0775129T3 (da) 3-Benzoylbenzofuranderivater som thyroidhormonantagonister
DE69926806D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
PT776324E (pt) Antagonista da endotelina
BR9813228A (pt) Formulação de 2-metil-tieno-benzodiazepina
DZ2495A1 (fr) Formule nouvelle de l'oméprazole-s.
EA199700117A1 (ru) Трициклические бензазепиновые антагонисты вазопрессина, способ их получения, фармацевтическая композиция и способ лечения млекопитающих с использованием трициклических бензазепинов
DE69512930D1 (de) Stilben-derivate verwendbar als cyclooxygenase-2 hemmer
NO963064D0 (no) Behandling av normotensive glaukoma med angiotensin-II-antagonister
DE69734321D1 (de) Non-peptidische vasopressin via antagonisten
JO2321B1 (en) 4-phenyl-pyridine derivatives
ATE304530T1 (de) Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen
BR9813208A (pt) Antagonista receptor de vitronectina
DE69614149D1 (de) Chinolinderivate als antimalariamittel
TNSN01175A1 (fr) Derives de piperidines antagonistes selectives de sous- types de recepteurs de nmda, et compositions les contenant.
WO2000076489A3 (fr) Procede d'inhibition de l'agregation de proteines amyloides et de formation d'images de depots amyloides
DK0978284T3 (da) Anvendelse af 15-keto-prostaglandin-E-forbindelser som endothelinantagonister
DE69721838D1 (de) 1-[1-(4-chlorphenyl)cyclobutyl]-3-methylbutyl amin derivate zur senkung von harnsäurespiegeln beim menschen
ATE277893T1 (de) N-(2-phenyl-4-amino-butyl)-1-naphthamide als neurokinin-1 rezeptorantagonisten
BR9812085A (pt) "método para a sìntese de derivados de quinolina"
AP1534A (en) Vitronectin receptor antagonists.
SE9702002D0 (sv) Novel compounds
NO20001548D0 (no) Endotelinantagonist og en renin-angiotensinsystem inhibitor som et kombinert preparat
EA200400416A1 (ru) Комбинация ингибитора pde и антагониста лейкотриенового рецептора